logo

FDMT Stock Gains Pre-Market After Positive Study Data For Experimental Drug In Eye Disease

The drug showed maintenance of visual acuity, control of retinal anatomy, and reduction of treatment burden at all time points with up to 2 years of follow-up.

Read Full

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *